EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY-NC-ND 4.0

Pan-immune-inflammation value is associated with all-cause and cause-specific mortality among individuals with cancer survivors: a population-based longitudinal cohort study

Juhua Dai, Xinping Sun, Bozhi Lin, Yujing Sun, Liyuan Chen

Cancer Treatment and Research Communications · 2026

DOI: 10.1016/j.ctarc.2025.101070 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Cancer Treatment and Research Communications, 2026. Verfasst von Juhua Dai und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory, Peking University International Hospital, 102206, Beijing, PR China. Hauptthemen laut MEDLINE: Cancer Survivors, Inflammation, Neoplasms, Cardiovascular Diseases. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: This study examines whether the pan-immune inflammation value (PIV) is linked to all-cause, cardiovascular disease (CVD), and cancer-specific mortality in individuals with a history of cancer. Data from the National Health and Nutrition Examination Survey (NHANES) were analyzed to further explore the potential mediating influence of estimated glomerular filtration rate (eGFR) on the PIV-mortality relationship. METHODS: We included 3773 cancer survivors from NHANES (2003-2018). Mortality follow-up was conducted via linkage to the National Death Index. Associations between PIV and mortality outcomes were assessed using restricted cubic spline curves and weighted multivariable Cox regression. Mediation analysis evaluated whether eGFR partly explains the effect of PIV on mortality. RESULTS: Over a median follow-up of 84.75 months, 1137 deaths occurred (all-cause: 30.14 %; CVD: 8.32 %; cancer: 9.09 %). Using an optimal cutoff of 344.63, participants were classified into low (n = 2335) and high PIV (n = 1438) groups. In fully adjusted models, high PIV was associated with increased risks of all-cause mortality (HR 1.36, 95 % CI 1.18-1.56) and cancer-related mortality (HR 1.42, 95 % CI 1.10-1.82). eGFR mediated 9.10 % of the association between PIV and all-cause mortality and 11.47 % for CVD mortality, but not significantly for cancer mortality. CONCLUSION: Elevated PIV independently predicts higher all-cause and cancer-specific mortality in cancer survivors. The findings suggest that PIV may serve as a practical prognostic marker, with renal function partially accounting for its link to mortality.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cancer SurvivorsInflammationNeoplasmsCardiovascular DiseasesHumansMaleFemaleMiddle AgedLongitudinal StudiesCause of DeathGlomerular Filtration RateAgedNutrition SurveysAdult

Stichwörter der Autor:innen

Cancer survivorsCardiovascular diseaseMortalityNHANESPan-immune inflammation value

Autor:innen und Institutionen

  • Department of Clinical Laboratory, Peking University International Hospital, 102206, Beijing, PR China.
  • Department of Clinical Laboratory, Peking University International Hospital, 102206, Beijing, PR China. Electronic address: sciencell2025@163.com.

Zitieren

APA

Dai, J., Sun, X., Lin, B., Sun, Y., & Chen, L. (2026). Pan-immune-inflammation value is associated with all-cause and cause-specific mortality among individuals with cancer survivors: a population-based longitudinal cohort study. Cancer Treatment and Research Communications. https://doi.org/10.1016/j.ctarc.2025.101070

Vancouver

Dai J, Sun X, Lin B, Sun Y, Chen L. Pan-immune-inflammation value is associated with all-cause and cause-specific mortality among individuals with cancer survivors: a population-based longitudinal cohort study. Cancer Treatment and Research Communications. 2026. doi:10.1016/j.ctarc.2025.101070

BibTeX
@article{Dai2026,
  author = {Dai, Juhua and Sun, Xinping and Lin, Bozhi and Sun, Yujing and Chen, Liyuan},
  title = {Pan-immune-inflammation value is associated with all-cause and cause-specific mortality among individuals with cancer survivors: a population-based longitudinal cohort study},
  journal = {Cancer Treatment and Research Communications},
  year = {2026},
  doi = {10.1016/j.ctarc.2025.101070}
}
Kostenlos starten →